ATE279175T1 - Pharmazeutische zusammensetzungen und verfahren zur verminderung des cellulite auftretens - Google Patents

Pharmazeutische zusammensetzungen und verfahren zur verminderung des cellulite auftretens

Info

Publication number
ATE279175T1
ATE279175T1 AT00957590T AT00957590T ATE279175T1 AT E279175 T1 ATE279175 T1 AT E279175T1 AT 00957590 T AT00957590 T AT 00957590T AT 00957590 T AT00957590 T AT 00957590T AT E279175 T1 ATE279175 T1 AT E279175T1
Authority
AT
Austria
Prior art keywords
skin
methods
fat
cellulite
appearance
Prior art date
Application number
AT00957590T
Other languages
English (en)
Inventor
Howard Murad
Original Assignee
Howard Murad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Howard Murad filed Critical Howard Murad
Application granted granted Critical
Publication of ATE279175T1 publication Critical patent/ATE279175T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AT00957590T 1999-08-20 2000-08-18 Pharmazeutische zusammensetzungen und verfahren zur verminderung des cellulite auftretens ATE279175T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15003499P 1999-08-20 1999-08-20
PCT/US2000/022790 WO2001013865A1 (en) 1999-08-20 2000-08-18 Pharmaceutical compositions and methods for reducing the appearance of cellulite

Publications (1)

Publication Number Publication Date
ATE279175T1 true ATE279175T1 (de) 2004-10-15

Family

ID=22532833

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00957590T ATE279175T1 (de) 1999-08-20 2000-08-18 Pharmazeutische zusammensetzungen und verfahren zur verminderung des cellulite auftretens

Country Status (7)

Country Link
US (2) US6358539B1 (de)
EP (1) EP1207840B1 (de)
JP (1) JP2003507400A (de)
AT (1) ATE279175T1 (de)
AU (1) AU6918700A (de)
DE (1) DE60014931D1 (de)
WO (1) WO2001013865A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3176658D1 (en) * 1981-12-10 1988-03-31 Revlon Process for making metallic leafing pigments
US6534086B1 (en) * 2000-03-06 2003-03-18 Metagenics, Inc. Composition and method for treatment of inflammation and pain in mammals
JP4182183B2 (ja) * 1999-08-24 2008-11-19 ディーエスエム アイピー アセッツ ビー．ブイ． 痩身用皮膚化粧料
US6808707B2 (en) * 2000-02-04 2004-10-26 Matrix Design Wound healing compositions and methods using tropoelastin and lysyl oxidase
IT1320080B1 (it) * 2000-10-25 2003-11-18 Giuliani Spa Composizione per uso farmaceutico o dietetico.
US6906045B2 (en) * 2001-03-09 2005-06-14 Wyeth Method for reducing malodor of chondroitin
US20020182237A1 (en) * 2001-03-22 2002-12-05 The Procter & Gamble Company Skin care compositions containing a sugar amine
US20050130321A1 (en) * 2001-04-23 2005-06-16 Nicholson Jeremy K. Methods for analysis of spectral data and their applications
DE10128911A1 (de) * 2001-06-15 2002-12-19 Beiersdorf Ag Verwendung von Ascorbinsäure zur Herstellung angiogenetisch wirksamer topischer Zubereitungen
DE10128818A1 (de) * 2001-06-15 2002-12-19 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus Ascorbinsäure und einem oder mehreren Biochinonen zur Herstellung angiogenetisch wirksamer topischer Zubereitungen
DE10128910A1 (de) * 2001-06-15 2002-12-19 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus Arginin und Ascorbinsäure zur Hautstraffung
WO2003002125A2 (en) * 2001-06-29 2003-01-09 Astion A/S Combination of aminosugars and cysteine or cysteine derivatives
US20030105034A1 (en) * 2001-07-05 2003-06-05 Astion Deveopment A/S Pyridine carboxy derivatives and an aminosugar
US7435722B2 (en) * 2001-08-31 2008-10-14 University Of Southern California Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability
CA2458821C (en) * 2001-08-31 2012-01-10 University Of Southern California Use of non-toxic crosslinking agents to inhibit mechanical degradation of collagenous tissues
US6594739B1 (en) * 2001-09-11 2003-07-15 Emc Corporation Memory system and method of using same
AU2002366800B2 (en) * 2001-12-20 2006-08-03 Femmepharma Holding Company, Inc. Vaginal delivery of drugs
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
AU2003284337B2 (en) 2002-10-25 2010-04-15 Precision Dermatology, Inc. Modulation of zinc levels to improve tissue properties
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US7812010B2 (en) * 2003-01-02 2010-10-12 Femmepharma, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20050123500A1 (en) * 2003-01-31 2005-06-09 The Procter & Gamble Company Means for improving the appearance of mammalian hair and nails
EP1587377A2 (de) * 2003-01-31 2005-10-26 The Procter & Gamble Company Mittel zur verbesserung deserscheinungsbilds von säugetier-keratingewebe
US20040161435A1 (en) * 2003-02-14 2004-08-19 Gupta Shyam K. Skin Firming Anti-Aging Cosmetic Mask Compositions
US7452527B2 (en) * 2003-03-28 2008-11-18 Murad, Inc. Methods of promoting hair growth
US20050043274A1 (en) * 2003-08-22 2005-02-24 Howard Murad Pharmaceutical compositions and methods for lowering blood pressure and pulse rate
JPWO2005027898A1 (ja) * 2003-09-19 2007-11-15 独立行政法人理化学研究所 アミノ酸組成物
US20050261367A1 (en) * 2004-03-29 2005-11-24 Howard Murad Methods for treating dermatological and other health-related conditions in a patient
JP4496375B2 (ja) * 2004-05-21 2010-07-07 国立大学法人鳥取大学 創傷の治療又は処置のための薬剤
BRPI0402260B1 (pt) * 2004-06-15 2015-02-18 Botica Com Farmaceutica Ltda Composição para produtos de higiene, cosméticos e perfumes.
US20050282772A1 (en) * 2004-06-21 2005-12-22 Gokaraju Ganga R New dietary supplement composition for obesity and inflammation
US20060130675A1 (en) * 2004-11-30 2006-06-22 Crawford David S Transdermal nutritional supplement delivery patch
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7854929B2 (en) 2005-01-21 2010-12-21 The Research Foundation Of State University Of New York Method for treating lateral epicondylitis using collagenase
US7252834B2 (en) * 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
CA2546464A1 (en) * 2005-05-04 2006-11-04 Richard Wachsberg Sequential application of oral and topical formulations for treating wrinkles and other damage to skin
US20070025950A1 (en) * 2005-07-28 2007-02-01 Elson Melvin L Composition and method for treating cellulite
US20070077220A1 (en) * 2005-09-30 2007-04-05 Ramirez Jose E Stable ascorbic acid compositions
US7700083B2 (en) * 2005-10-24 2010-04-20 Kevin Meehan Skin care composition for accelerated production of collagen proteins and method of fabricating same
US20090069638A1 (en) * 2005-12-02 2009-03-12 Howard Murad Diagnostic and Treatment Regimen for Achieving Body Water Homeostasis
US20070269534A1 (en) * 2006-02-02 2007-11-22 Ramirez Jose E Methods of treating skin to enhance therapeutic treatment thereof
US20070178058A1 (en) * 2006-02-02 2007-08-02 Ramirez Jose E Methods of using stable ascorbic acid compositions
WO2007100590A2 (en) * 2006-02-22 2007-09-07 Auxilium Pharmaceuticals, Inc. Methods for treating cellulite
WO2007120606A2 (en) * 2006-04-10 2007-10-25 President And Fellows Of Harvard College Methods for modulating formation and progression of cellulite
FR2907335B1 (fr) * 2006-10-20 2009-08-21 Inneov Lab Utilisation cosmetique par voie orale et/ou parenterale de la glucosamine.
BRPI0717458A8 (pt) * 2006-10-20 2017-06-06 Laboratoires Inneov Utilização cosmética por via oral e/ou parenteral da glicosamina e da associação da glicosamina e pelo menos um composto polifenol, processo cosmético, composição para administração oral, e, complemento alimentar ou alimento funcional
US20080127296A1 (en) * 2006-11-29 2008-05-29 International Business Machines Corporation Identity assurance method and system
EP2104489A2 (de) * 2006-12-26 2009-09-30 FemmePharma Holding Company, Inc. Topische verabreichung von danazol
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
US20090155337A1 (en) * 2007-11-12 2009-06-18 Endologix, Inc. Method and agent for in-situ stabilization of vascular tissue
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US20090269425A1 (en) * 2008-04-28 2009-10-29 Truscott Kent J Formulation and method for relieving or preventing symptoms associated with uric acid crystals
CA2737219C (en) 2008-08-11 2017-02-28 Tracy Keller Halofuginone analogs for inhibition of trna synthetases and uses thereof
PT104241B (pt) * 2008-10-29 2012-03-06 Stargate Produtos Farmaceuticos Dieteticos E Nutricionais Lda Composições incorporando agentes redutores da celulite e inestetismos associados e formulações que as contêm
US20100261662A1 (en) * 2009-04-09 2010-10-14 Endologix, Inc. Utilization of mural thrombus for local drug delivery into vascular tissue
US20100273207A1 (en) * 2009-04-24 2010-10-28 Raymond Langley Methods for Diagnosis of Sepsis and Risk of Death
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
WO2011044455A1 (en) * 2009-10-09 2011-04-14 Vatrix Medical, Inc. In vivo chemical stabilization of vulnerable plaque
WO2011116220A2 (en) * 2010-03-17 2011-09-22 Arbonne International Llc Oral supplement
JP2012117827A (ja) * 2010-11-29 2012-06-21 Shiseido Co Ltd オキシタラン線維を指標とした肌理評価法
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
US9937255B2 (en) 2011-05-18 2018-04-10 Nectero Medical, Inc. Coated balloons for blood vessel stabilization
EP4772625A2 (de) 2012-01-12 2026-07-08 Endo Biologics Limited Clostridium histolyticum enzym
CA2861840C (en) 2012-01-13 2020-12-15 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
US9283241B2 (en) 2012-07-10 2016-03-15 Clemson University Treatment to render implants resistant to diabetes
US9636385B2 (en) 2012-10-24 2017-05-02 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
MX395526B (es) * 2015-10-28 2025-03-25 Indena Spa Composiciones y su uso en conservacion de alimentos.
IT201600075108A1 (it) * 2016-07-18 2018-01-18 Italfarmacia S R L 00155 Roma / It Composizione e metodo cosmetico per ridurre gli inestetismi della cellulite.
DK3589204T3 (da) 2017-03-01 2025-06-30 Endo Operations Ltd Apparat og fremgangsmåde til vurdering og behandling af cellulitis
KR20250171475A (ko) 2017-03-28 2025-12-08 엔도 오퍼레이션즈 리미티드 개선된 콜라게나제 생성 방법
JP2019081726A (ja) * 2017-10-30 2019-05-30 日光ケミカルズ株式会社 エラスターゼ活性阻害剤
CN111819632B (zh) 2018-01-29 2021-09-14 艾托拉皮肤健康公司 用于对个性化护肤产品制定配方的系统和方法
WO2019237125A1 (en) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB896940A (en) 1959-02-26 1962-05-23 Pfizer & Co C Healing agent for wounds of the body surface
US3232836A (en) 1959-08-24 1966-02-01 Pfizer & Co C Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine
DE1792346C3 (de) 1968-08-22 1980-10-23 Rotta Research Laboratorium S.P.A., San Fruttuoso Di Monza, Mailand (Italien) Pharmazeutisches Präparat für die Behandlung von degenerativen Gelenkerkrankungen
US3773930A (en) 1971-03-23 1973-11-20 Johnson & Johnson Amino acid composition
US4285964A (en) 1979-08-30 1981-08-25 Continental Pharma Salts of (+)-catechine, their preparation and use, and compositions containing these salts
US4414202A (en) 1980-02-19 1983-11-08 Silvetti Anthony N Composition for treatment of wounds
US4486416A (en) 1981-03-02 1984-12-04 Soll David B Protection of human and animal cells subject to exposure to trauma
IT1148050B (it) 1981-04-30 1986-11-26 Rotta Research Lab Composto stabile della glucosamina solfato procedimento per la sua preparazione e composizioni farmaceutiche contenenti tale composto
EP0066283B1 (de) 1981-06-02 1986-09-10 Eupan Corporation Eustatische Zusammensetzung zur nichtspezifischen Ermöglichung und Verstärkung der gesamten homeostatischen Regulierung und Instandhaltung, Kompensierung und Ausbesserung in lebenden Organismen
US4424232A (en) 1982-05-19 1984-01-03 Parkinson Richard W Treatment of herpes simplex
US4518614A (en) 1982-11-04 1985-05-21 Redken Laboratories, Inc. Cosmetic preparation
US4716224A (en) 1984-05-04 1987-12-29 Seikagaku Kogyo Co. Ltd. Crosslinked hyaluronic acid and its use
US4863907A (en) 1984-06-29 1989-09-05 Seikagaku Kogyo Co., Ltd. Crosslinked glycosaminoglycans and their use
US4647453A (en) 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
US5371089A (en) 1987-02-26 1994-12-06 Senetek, Plc Method and composition for ameliorating the adverse effects of aging
FR2619313B1 (fr) * 1987-08-14 1989-12-29 Claude Christophe Nouvelles compositions d'elements mineraux et/ou oligoelements et leur procede de preparation
FR2623396B1 (fr) 1987-11-25 1990-03-30 Sanofi Sa Utilisation de l'ademetionine contre le vieillissement de la peau
US4938969A (en) 1988-11-14 1990-07-03 Milor Scientific, Ltd. Method for the treatment of aging or photo-damaged skin
IL91928A (en) 1989-10-08 1994-07-31 Amrad Res & Dev Pharmaceutical compositions containing prolactin
US5153174A (en) 1989-10-30 1992-10-06 Union Carbide Chemicals & Plastics Inc. Polymer mixtures useful in skin care
JPH0429915A (ja) 1990-05-24 1992-01-31 Sunstar Inc 光破砕性リポソーム含有皮膚化粧料
US5308627A (en) 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
DE69207254T2 (de) 1991-04-18 1996-09-05 Zeneca Ltd Bisphenolderivate und ihre Verwendung als Beschichtungsmittel
US5198465A (en) 1991-06-19 1993-03-30 Dioguardi Francesco S Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen
US5296500A (en) 1991-08-30 1994-03-22 The Procter & Gamble Company Use of N-acetyl-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy
US5281196A (en) 1992-05-22 1994-01-25 Sultenfuss Thomas J Skin treatment composition and method of use
US5364845C1 (en) 1993-03-31 2002-09-10 Nutramax Lab Inc Glusosamine chondroitin and manganese composition for the protection and repair of connective tissue
ES2118195T3 (es) 1993-10-22 1998-09-16 Shiseido Co Ltd Composicion topica que contiene tocoferol.
US5529769A (en) 1994-12-20 1996-06-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions containing betulinic acid
US5730988A (en) * 1995-04-20 1998-03-24 Lynntech, Inc. Nutritional supplements for improving glucose metabolism
IT1288257B1 (it) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
US5804168A (en) * 1997-01-29 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for protecting and treating sun damaged skin
US6156347A (en) * 1998-01-21 2000-12-05 Bio-Dar Ltd. Controlled release chromium picolinate
WO1999047118A1 (en) 1998-03-16 1999-09-23 The Procter & Gamble Company Compositions for regulating skin appearance
JP2002506801A (ja) 1998-03-16 2002-03-05 ザ、プロクター、エンド、ギャンブル、カンパニー 哺乳類の皮膚のセルライトを軽減する方法

Also Published As

Publication number Publication date
DE60014931D1 (de) 2004-11-18
AU6918700A (en) 2001-03-19
US6676977B2 (en) 2004-01-13
WO2001013865A1 (en) 2001-03-01
US6358539B1 (en) 2002-03-19
US20020137691A1 (en) 2002-09-26
JP2003507400A (ja) 2003-02-25
EP1207840A1 (de) 2002-05-29
EP1207840A4 (de) 2002-10-30
EP1207840B1 (de) 2004-10-13

Similar Documents

Publication Publication Date Title
DE60014931D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verminderung des cellulite auftretens
US5198465A (en) Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen
MX2009002921A (es) Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
MX2007006707A (es) Acidos grasos omega-3 y agente dislipidemico para terapia lipidica.
BR0315088A (pt) Métodos para produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente e para tratamento de câncer em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6474 ou de um sal fermaceuticamento aceitável do mesmo e gencitabina
ATE268179T1 (de) Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung
MX2009002924A (es) Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos.
BR0313117A (pt) Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável
PT1677806E (pt) Métodos para tratamento de entorse e distensão muscular aguda e por excesso de esforço utilizando ácido hialurónico
KR950031063A (ko) 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
WO2009150214A3 (en) Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
DE60330888D1 (de) Verwendung von drospirenon zur behandlung von hypertension
DE60111515D1 (de) Kombinationstherapie mit keratinozyten-wachstumfaktor und ein epidermis-wachstumfaktor inhibitor
EP1557163A4 (de) Therapeutikum zur kontraktion vonschleimhaut, verfahren zur behandlung von erkrankungen von schleimhäuten,injektionsgerät und therapeutisches set
US20040086581A1 (en) Bio-energetic joint and arthritis pain formula
NO20055390L (no) Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer
MX366496B (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.
PT1251850E (pt) Utilizacao de uma preparacao de combinacao na terapia do cancro
BRPI0412408A (pt) métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste
WO2003024486A1 (en) Remedies for bone loss
SE0200598D0 (sv) Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences
Rai et al. Split skin grafting for leg ulcers complicating rheumatoid arthritis
MD885G2 (ro) Metodă de tratament al colitei, hepatitei, pielonefritei, maladiilor alergice ale tegumentelor şi căilor respiratorii
UA37540A (uk) Спосіб лікування діабетичних ангіопатій у хворих на туберкульоз

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties